Literature DB >> 109340

Insulin resistance caused by massive degradation of subcutaneous insulin.

E P Paulsen, J W Courtney, W C Duckworth.   

Abstract

Severe resistance to subcutaneous insulin but sensitivity to intravenous insulin persisted for 15 months in a 17-year-old diabetic girl. Heat-labile insulin-degrading activity was present in the patient's ketotic sera and in the 100,000 g fraction (soluble fraction) of adipose tissue. Serum-degrading activity was not inhibited by N-ethylmaleimide. The soluble fraction also degraded glucagon and B chain but not growth hormone or myoglobin. It was inhibited by incubation with the patient's nonketotic sera, normal sera, or Trasylol. Glutathione-insulin-transhydrogenase (GIT) activity was 66% of normal. The biopsy of adipose tissue at remission showed a normal level of insulin- and glucagon-degrading activity. The activity was eluted from Sephadex G200 as a single peak and had properties consistent with those of the insulin-specific protease (ISP). The increased degrading activity present during insulin resistance had properties not shared with ISP, suggesting the presence of an uncharacterized protease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 109340     DOI: 10.2337/diab.28.7.640

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  31 in total

1.  Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model.

Authors:  S A Charman; D N McLennan; G A Edwards; C J Porter
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

2.  'Brittle' diabetes.

Authors:  G Williams; G V Gill; J C Pickup
Journal:  BMJ       Date:  1991-09-21

3.  "Brittle" diabetes.

Authors:  S A Amiel
Journal:  BMJ       Date:  1991-08-03

4.  Analysis of "A New Optimized Percutaneous Access System for CIPII".

Authors:  Eric Renard
Journal:  J Diabetes Sci Technol       Date:  2017-04-13

5.  Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus.

Authors:  Sarika Gupta; Tandrika Chattopadhyay; Mahendra Pal Singh; Avadhesha Surolia
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-13       Impact factor: 11.205

6.  Brittle diabetes.

Authors:  R Tattersall
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-31

7.  The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites.

Authors:  J D Jensen; L W Jensen; J K Madsen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Insulin degrading enzyme activity and insulin binding of erythrocytes in normal subjects and Type 2 (non-insulin-dependent) diabetic patients.

Authors:  E Standl; H J Kolb
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

9.  Continuous insulin delivery systems for the pregnant diabetic patient.

Authors:  H M Hofmann; P A Weiss; J G Haas
Journal:  Acta Diabetol Lat       Date:  1986 Jul-Sep

10.  Biochemical and clinical implications of proinsulin conversion intermediates.

Authors:  B D Given; R M Cohen; S E Shoelson; B H Frank; A H Rubenstein; H S Tager
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.